APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Embolism Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pulmonary Embolism Drug Industry Growth and Trends Forecast to 2032

26 December 202593 pages

Choose your research edition.

Industry ResearchPulmonary Embolism Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Embolism Drug Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Pulmonary Embolism Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Embolism Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Embolism Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Pulmonary Embolism Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pulmonary Embolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pulmonary Embolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Embolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pulmonary Embolism Drug include F. Hoffmann-La Roche Ltd., Genentech, Inc., Verseon Corp, Dong-A Socio Holdings Co. Ltd. and Accu-Break Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pulmonary Embolism Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pulmonary Embolism Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pulmonary Embolism Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pulmonary Embolism Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Pulmonary Embolism Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pulmonary Embolism Drug Market by Company

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Verseon Corp

Dong-A Socio Holdings Co. Ltd.

Accu-Break Pharmaceuticals, Inc.

Pulmonary Embolism Drug Segment by Type

DS-1040

DS-9231

TRX-1

Others

Pulmonary Embolism Drug Segment by Application

Hospital

Clinic

Others

Pulmonary Embolism Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Embolism Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Embolism Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Embolism Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pulmonary Embolism Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Pulmonary Embolism Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of DS-1040 Table 2. Major Company of DS-9231 Table 3. Major Company of TRX-1 Table 4. Major Company of Others Table 5. Global Pulmonary Embolism Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Pulmonary Embolism Drug Sales by Type (2021-2026) & (W Units) Table 7. Global Pulmonary Embolism Drug Sales Market Share in Volume by Type (2021-2026) Table 8. Global Pulmonary Embolism Drug Sales by Type (2021-2026) & (US$ Million) Table 9. Global Pulmonary Embolism Drug Sales Market Share in Value by Type (2021-2026) Table 10. Global Pulmonary Embolism Drug Price by Type (2021-2026) & (US$/Unit) Table 11. Global Pulmonary Embolism Drug Sales by Type (2027-2032) & (W Units) Table 12. Global Pulmonary Embolism Drug Sales Market Share in Volume by Type (2027-2032) Table 13. Global Pulmonary Embolism Drug Sales by Type (2027-2032) & (US$ Million) Table 14. Global Pulmonary Embolism Drug Sales Market Share in Value by Type (2027-2032) Table 15. Global Pulmonary Embolism Drug Price by Type (2027-2032) & (US$/Unit) Table 16. North America Pulmonary Embolism Drug Sales by Type (2021-2026) & (W Units) Table 17. North America Pulmonary Embolism Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Pulmonary Embolism Drug Sales by Type (2021-2026) & (W Units) Table 19. Europe Pulmonary Embolism Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Pulmonary Embolism Drug Sales by Type (2021-2026) & (W Units) Table 21. Asia-Pacific Pulmonary Embolism Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Pulmonary Embolism Drug Sales by Type (2021-2026) & (W Units) Table 23. Latin America Pulmonary Embolism Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Pulmonary Embolism Drug Sales by Type (2021-2026) & (W Units) Table 25. Middle East and Africa Pulmonary Embolism Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Pulmonary Embolism Drug Industry Trends Table 27. Pulmonary Embolism Drug Industry Drivers Table 28. Pulmonary Embolism Drug Industry Opportunities and Challenges Table 29. Pulmonary Embolism Drug Industry Restraints Table 30. Global Pulmonary Embolism Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Pulmonary Embolism Drug Revenue Market Share by Company (2021-2026) Table 32. Global Pulmonary Embolism Drug Sales by Company (2021-2026) & (W Units) Table 33. Global Pulmonary Embolism Drug Sales Share by Company (2021-2026) Table 34. Global Pulmonary Embolism Drug Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Pulmonary Embolism Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Pulmonary Embolism Drug Major Company Production Sites and Headquarters Table 37. Global Pulmonary Embolism Drug Company, Product Type & Application Table 38. Global Pulmonary Embolism Drug Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Pulmonary Embolism Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Pulmonary Embolism Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Pulmonary Embolism Drug Sales by Region (2021-2026) & (W Units) Table 43. Global Pulmonary Embolism Drug Sales Market Share in Volume by Region (2021-2026) Table 44. Global Pulmonary Embolism Drug Sales by Region (2021-2026) & (US$ Million) Table 45. Global Pulmonary Embolism Drug Sales Market Share in Value by Region (2021-2026) Table 46. Global Pulmonary Embolism Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Pulmonary Embolism Drug Sales by Region (2027-2032) & (W Units) Table 48. Global Pulmonary Embolism Drug Sales Market Share in Volume by Region (2027-2032) Table 49. Global Pulmonary Embolism Drug Sales by Region (2027-2032) & (US$ Million) Table 50. Global Pulmonary Embolism Drug Sales Market Share in Value by Region (2027-2032) Table 51. Global Pulmonary Embolism Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Pulmonary Embolism Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Pulmonary Embolism Drug Sales by Application (2021-2026) & (W Units) Table 54. Global Pulmonary Embolism Drug Sales Market Share in Volume by Application (2021-2026) Table 55. Global Pulmonary Embolism Drug Sales by Application (2021-2026) & (US$ Million) Table 56. Global Pulmonary Embolism Drug Sales Market Share in Value by Application (2021-2026) Table 57. Global Pulmonary Embolism Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global Pulmonary Embolism Drug Sales by Application (2027-2032) & (W Units) Table 59. Global Pulmonary Embolism Drug Sales Market Share in Volume by Application (2027-2032) Table 60. Global Pulmonary Embolism Drug Sales by Application (2027-2032) & (US$ Million) Table 61. Global Pulmonary Embolism Drug Sales Market Share in Value by Application (2027-2032) Table 62. Global Pulmonary Embolism Drug Price by Application (2027-2032) & (US$/Unit) Table 63. North America Pulmonary Embolism Drug Sales by Application (2021-2026) & (W Units) Table 64. North America Pulmonary Embolism Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Pulmonary Embolism Drug Sales by Application (2021-2026) & (W Units) Table 66. Europe Pulmonary Embolism Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Pulmonary Embolism Drug Sales by Application (2021-2026) & (W Units) Table 68. Asia-Pacific Pulmonary Embolism Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Pulmonary Embolism Drug Sales by Application (2021-2026) & (W Units) Table 70. Latin America Pulmonary Embolism Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Pulmonary Embolism Drug Sales by Application (2021-2026) & (W Units) Table 72. Middle East and Africa Pulmonary Embolism Drug Sales by Application (2021-2026) & (US$ Million) Table 73. F. Hoffmann-La Roche Ltd. Company Information Table 74. F. Hoffmann-La Roche Ltd. Business Overview Table 75. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolio Table 77. F. Hoffmann-La Roche Ltd. Recent Development Table 78. Genentech, Inc. Company Information Table 79. Genentech, Inc. Business Overview Table 80. Genentech, Inc. Pulmonary Embolism Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Genentech, Inc. Pulmonary Embolism Drug Product Portfolio Table 82. Genentech, Inc. Recent Development Table 83. Verseon Corp Company Information Table 84. Verseon Corp Business Overview Table 85. Verseon Corp Pulmonary Embolism Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Verseon Corp Pulmonary Embolism Drug Product Portfolio Table 87. Verseon Corp Recent Development Table 88. Dong-A Socio Holdings Co. Ltd. Company Information Table 89. Dong-A Socio Holdings Co. Ltd. Business Overview Table 90. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolio Table 92. Dong-A Socio Holdings Co. Ltd. Recent Development Table 93. Accu-Break Pharmaceuticals, Inc. Company Information Table 94. Accu-Break Pharmaceuticals, Inc. Business Overview Table 95. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolio Table 97. Accu-Break Pharmaceuticals, Inc. Recent Development Table 98. North America Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 99. North America Pulmonary Embolism Drug Sales by Country (2021-2026) & (W Units) Table 100. North America Pulmonary Embolism Drug Sales Market Share by Country (2021-2026) Table 101. North America Pulmonary Embolism Drug Sales Forecast by Country (2027-2032) & (W Units) Table 102. North America Pulmonary Embolism Drug Sales Market Share Forecast by Country (2027-2032) Table 103. North America Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. North America Pulmonary Embolism Drug Market Size by Country (2021-2026) & (US$ Million) Table 105. North America Pulmonary Embolism Drug Market Share by Country (2021-2026) Table 106. North America Pulmonary Embolism Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. North America Pulmonary Embolism Drug Market Share Forecast by Country (2027-2032) Table 108. Europe Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 109. Europe Pulmonary Embolism Drug Sales by Country (2021-2026) & (W Units) Table 110. Europe Pulmonary Embolism Drug Sales Market Share by Country (2021-2026) Table 111. Europe Pulmonary Embolism Drug Sales Forecast by Country (2027-2032) & (W Units) Table 112. Europe Pulmonary Embolism Drug Sales Market Share Forecast by Country (2027-2032) Table 113. Europe Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Europe Pulmonary Embolism Drug Market Size by Country (2021-2026) & (US$ Million) Table 115. Europe Pulmonary Embolism Drug Market Share by Country (2021-2026) Table 116. Europe Pulmonary Embolism Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Europe Pulmonary Embolism Drug Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Pulmonary Embolism Drug Sales by Country (2021-2026) & (W Units) Table 120. Asia-Pacific Pulmonary Embolism Drug Sales Market Share by Country (2021-2026) Table 121. Asia-Pacific Pulmonary Embolism Drug Sales Forecast by Country (2027-2032) & (W Units) Table 122. Asia-Pacific Pulmonary Embolism Drug Sales Market Share Forecast by Country (2027-2032) Table 123. Asia-Pacific Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Asia-Pacific Pulmonary Embolism Drug Market Size by Country (2021-2026) & (US$ Million) Table 125. Asia-Pacific Pulmonary Embolism Drug Market Share by Country (2021-2026) Table 126. Asia-Pacific Pulmonary Embolism Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Asia-Pacific Pulmonary Embolism Drug Market Share Forecast by Country (2027-2032) Table 128. Latin America Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 129. Latin America Pulmonary Embolism Drug Sales by Country (2021-2026) & (W Units) Table 130. Latin America Pulmonary Embolism Drug Sales Market Share by Country (2021-2026) Table 131. Latin America Pulmonary Embolism Drug Sales Forecast by Country (2027-2032) & (W Units) Table 132. Latin America Pulmonary Embolism Drug Sales Market Share Forecast by Country (2027-2032) Table 133. Latin America Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Latin America Pulmonary Embolism Drug Market Size by Country (2021-2026) & (US$ Million) Table 135. Latin America Pulmonary Embolism Drug Market Share by Country (2021-2026) Table 136. Latin America Pulmonary Embolism Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Latin America Pulmonary Embolism Drug Market Share Forecast by Country (2027-2032) Table 138. Middle East and Africa Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 139. Middle East and Africa Pulmonary Embolism Drug Sales by Country (2021-2026) & (W Units) Table 140. Middle East and Africa Pulmonary Embolism Drug Sales Market Share by Country (2021-2026) Table 141. Middle East and Africa Pulmonary Embolism Drug Sales Forecast by Country (2027-2032) & (W Units) Table 142. Middle East and Africa Pulmonary Embolism Drug Sales Market Share Forecast by Country (2027-2032) Table 143. Middle East and Africa Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Middle East and Africa Pulmonary Embolism Drug Market Size by Country (2021-2026) & (US$ Million) Table 145. Middle East and Africa Pulmonary Embolism Drug Market Share by Country (2021-2026) Table 146. Middle East and Africa Pulmonary Embolism Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Pulmonary Embolism Drug Market Share Forecast by Country (2027-2032) Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Pulmonary Embolism Drug Distributors List Table 151. Pulmonary Embolism Drug Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Pulmonary Embolism Drug Image Figure 2. Global Pulmonary Embolism Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Embolism Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Embolism Drug Sales (2021-2032) & (W Units) Figure 5. DS-1040 Image Figure 6. Global DS-1040 Sales YoY Growth (2021-2032) & (W Units) Figure 7. DS-9231 Image Figure 8. Global DS-9231 Sales YoY Growth (2021-2032) & (W Units) Figure 9. TRX-1 Image Figure 10. Global TRX-1 Sales YoY Growth (2021-2032) & (W Units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 13. Global Pulmonary Embolism Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Pulmonary Embolism Drug Market Share by Type 2025 VS 2032 Figure 15. North America Pulmonary Embolism Drug Sales Market Share in Volume by Type in 2025 Figure 16. North America Pulmonary Embolism Drug Sales Market Share in Value by Type in 2025 Figure 17. Europe Pulmonary Embolism Drug Sales Market Share in Volume by Type in 2025 Figure 18. Europe Pulmonary Embolism Drug Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Pulmonary Embolism Drug Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Pulmonary Embolism Drug Sales Market Share in Value by Type in 2025 Figure 21. Latin America Pulmonary Embolism Drug Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Pulmonary Embolism Drug Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Pulmonary Embolism Drug Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Pulmonary Embolism Drug Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Pulmonary Embolism Drug Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 33. Global Pulmonary Embolism Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Pulmonary Embolism Drug Market Share by Application 2025 VS 2032 Figure 35. North America Pulmonary Embolism Drug Sales Market Share in Volume by Application in 2025 Figure 36. North America Pulmonary Embolism Drug Sales Market Share in Value by Application in 2025 Figure 37. Europe Pulmonary Embolism Drug Sales Market Share in Volume by Application in 2025 Figure 38. Europe Pulmonary Embolism Drug Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Pulmonary Embolism Drug Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Pulmonary Embolism Drug Sales Market Share in Value by Application in 2025 Figure 41. Latin America Pulmonary Embolism Drug Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Pulmonary Embolism Drug Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Pulmonary Embolism Drug Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Pulmonary Embolism Drug Sales Market Share in Value by Application in 2025 Figure 45. North America Pulmonary Embolism Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 46. North America Pulmonary Embolism Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Pulmonary Embolism Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Pulmonary Embolism Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Pulmonary Embolism Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. Europe Pulmonary Embolism Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Pulmonary Embolism Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Pulmonary Embolism Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Pulmonary Embolism Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Asia-Pacific Pulmonary Embolism Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Pulmonary Embolism Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Pulmonary Embolism Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Pulmonary Embolism Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Latin America Pulmonary Embolism Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Pulmonary Embolism Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Pulmonary Embolism Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Pulmonary Embolism Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Middle East and Africa Pulmonary Embolism Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Pulmonary Embolism Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Pulmonary Embolism Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Pulmonary Embolism Drug Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Pulmonary Embolism Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • DS-1040
  • DS-9231
  • TRX-1
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Verseon Corp
  • Dong-A Socio Holdings Co. Ltd.
  • Accu-Break Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Embolism Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Pulmonary Embolism Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Pulmonary Embolism Drug Market by Type
  6. 1.3.1 DS-1040
  7. 1.3.2 DS-9231
  8. 1.3.3 TRX-1
  9. 1.3.4 Others
  10. 1.4 Global Pulmonary Embolism Drug Market Size by Type
  11. 1.4.1 Global Pulmonary Embolism Drug Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Pulmonary Embolism Drug Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Pulmonary Embolism Drug Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Pulmonary Embolism Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Pulmonary Embolism Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Pulmonary Embolism Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Pulmonary Embolism Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Pulmonary Embolism Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Pulmonary Embolism Drug Industry Trends
  2. 2.2 Pulmonary Embolism Drug Industry Drivers
  3. 2.3 Pulmonary Embolism Drug Industry Opportunities and Challenges
  4. 2.4 Pulmonary Embolism Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Pulmonary Embolism Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Pulmonary Embolism Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Pulmonary Embolism Drug Price (2021-2026)
  4. 3.4 Global Pulmonary Embolism Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pulmonary Embolism Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Pulmonary Embolism Drug Company, Product Type & Application
  7. 3.7 Global Pulmonary Embolism Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pulmonary Embolism Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pulmonary Embolism Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pulmonary Embolism Drug Tier 1, Tier 2, and Tier 3
4 Pulmonary Embolism Drug Regional Status and Outlook
  1. 4.1 Global Pulmonary Embolism Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Pulmonary Embolism Drug Historic Market Size by Region
  3. 4.2.1 Global Pulmonary Embolism Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Pulmonary Embolism Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Pulmonary Embolism Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Pulmonary Embolism Drug Forecasted Market Size by Region
  7. 4.3.1 Global Pulmonary Embolism Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Pulmonary Embolism Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Pulmonary Embolism Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Pulmonary Embolism Drug by Application
  1. 5.1 Pulmonary Embolism Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Pulmonary Embolism Drug Market Size by Application
  6. 5.2.1 Global Pulmonary Embolism Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Pulmonary Embolism Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Pulmonary Embolism Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Pulmonary Embolism Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Pulmonary Embolism Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Pulmonary Embolism Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Pulmonary Embolism Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Pulmonary Embolism Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 F. Hoffmann-La Roche Ltd.
  2. 6.1.1 F. Hoffmann-La Roche Ltd. Company Information
  3. 6.1.2 F. Hoffmann-La Roche Ltd. Business Overview
  4. 6.1.3 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolio
  6. 6.1.5 F. Hoffmann-La Roche Ltd. Recent Developments
  7. 6.2 Genentech, Inc.
  8. 6.2.1 Genentech, Inc. Company Information
  9. 6.2.2 Genentech, Inc. Business Overview
  10. 6.2.3 Genentech, Inc. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Genentech, Inc. Pulmonary Embolism Drug Product Portfolio
  12. 6.2.5 Genentech, Inc. Recent Developments
  13. 6.3 Verseon Corp
  14. 6.3.1 Verseon Corp Company Information
  15. 6.3.2 Verseon Corp Business Overview
  16. 6.3.3 Verseon Corp Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Verseon Corp Pulmonary Embolism Drug Product Portfolio
  18. 6.3.5 Verseon Corp Recent Developments
  19. 6.4 Dong-A Socio Holdings Co. Ltd.
  20. 6.4.1 Dong-A Socio Holdings Co. Ltd. Company Information
  21. 6.4.2 Dong-A Socio Holdings Co. Ltd. Business Overview
  22. 6.4.3 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolio
  24. 6.4.5 Dong-A Socio Holdings Co. Ltd. Recent Developments
  25. 6.5 Accu-Break Pharmaceuticals, Inc.
  26. 6.5.1 Accu-Break Pharmaceuticals, Inc. Company Information
  27. 6.5.2 Accu-Break Pharmaceuticals, Inc. Business Overview
  28. 6.5.3 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolio
  30. 6.5.5 Accu-Break Pharmaceuticals, Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Pulmonary Embolism Drug Sales by Country
  2. 7.1.1 North America Pulmonary Embolism Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Pulmonary Embolism Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Pulmonary Embolism Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Pulmonary Embolism Drug Market Size by Country
  6. 7.2.1 North America Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Pulmonary Embolism Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Pulmonary Embolism Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Pulmonary Embolism Drug Sales by Country
  2. 8.1.1 Europe Pulmonary Embolism Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Pulmonary Embolism Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Pulmonary Embolism Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Pulmonary Embolism Drug Market Size by Country
  6. 8.2.1 Europe Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Pulmonary Embolism Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Pulmonary Embolism Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Pulmonary Embolism Drug Sales by Country
  2. 9.1.1 Asia-Pacific Pulmonary Embolism Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Pulmonary Embolism Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Pulmonary Embolism Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Pulmonary Embolism Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Pulmonary Embolism Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Pulmonary Embolism Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Pulmonary Embolism Drug Sales by Country
  2. 10.1.1 South America Pulmonary Embolism Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Pulmonary Embolism Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Pulmonary Embolism Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Pulmonary Embolism Drug Market Size by Country
  6. 10.2.1 South America Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Pulmonary Embolism Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Pulmonary Embolism Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Pulmonary Embolism Drug Sales by Country
  2. 11.1.1 Middle East and Africa Pulmonary Embolism Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Pulmonary Embolism Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Pulmonary Embolism Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Pulmonary Embolism Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Pulmonary Embolism Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Pulmonary Embolism Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Pulmonary Embolism Drug Value Chain Analysis
  2. 12.1.1 Pulmonary Embolism Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Pulmonary Embolism Drug Production Mode & Process
  7. 12.2 Pulmonary Embolism Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Pulmonary Embolism Drug Distributors
  10. 12.2.3 Pulmonary Embolism Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst